Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Challenges and Opportunities for Quantitative Clinical Pharmacology in Cancer Immunotherapy: Something Old, Something New, Something Borrowed, and Something Blue.
Stroh M, Carlile DJ, Li CC, Wagg J, Ribba B, Ramanujan S, Jin J, Xu J, Charoin JE, Xhu ZX, Morcos PN, Davis JD, Phipps A. Stroh M, et al. Among authors: phipps a. CPT Pharmacometrics Syst Pharmacol. 2015 Sep;4(9):495-7. doi: 10.1002/psp4.12014. Epub 2015 Sep 11. CPT Pharmacometrics Syst Pharmacol. 2015. PMID: 26451328 Free PMC article.
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Morcos PN, Yu L, Bogman K, Sato M, Katsuki H, Kawashima K, Moore DJ, Whayman M, Nieforth K, Heinig K, Guerini E, Muri D, Martin-Facklam M, Phipps A. Morcos PN, et al. Among authors: phipps a. Xenobiotica. 2017 Mar;47(3):217-229. doi: 10.1080/00498254.2016.1179821. Epub 2016 May 16. Xenobiotica. 2017. PMID: 27180975
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
Morcos PN, Parrott N, Banken L, Timpe C, Lindenberg M, Guerini E, Dall G, Bogman K, Sturm C, Zeaiter A, Martin-Facklam M, Phipps A. Morcos PN, et al. Among authors: phipps a. Clin Pharmacol Drug Dev. 2017 May;6(3):266-279. doi: 10.1002/cpdd.299. Epub 2016 Oct 3. Clin Pharmacol Drug Dev. 2017. PMID: 27545871 Clinical Trial.
Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors.
Meneses-Lorente G, Bentley D, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Brink A, Djebli N, Mercier F, Buchheit V, Phipps A. Meneses-Lorente G, et al. Among authors: phipps a. Invest New Drugs. 2021 Jun;39(3):803-811. doi: 10.1007/s10637-020-01047-5. Epub 2021 Jan 18. Invest New Drugs. 2021. PMID: 33462752 Free PMC article. Clinical Trial.
In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK).
Meneses-Lorente G, Fowler S, Guerini E, Kowalski K, Chow-Maneval E, Yu L, Mercier F, Ullah M, Umehara K, Brink A, Buchheit V, Zwanziger E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: phipps a. Invest New Drugs. 2022 Feb;40(1):68-80. doi: 10.1007/s10637-021-01156-9. Epub 2021 Aug 21. Invest New Drugs. 2022. PMID: 34417912 Free PMC article.
Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations.
Meneses-Lorente G, Guerini E, Mercier F, Parrott N, Kowalski K, Chow-Maneval E, Buchheit V, Bergthold G, Fox E, Phipps A, Djebli N. Meneses-Lorente G, et al. Among authors: phipps a. Cancer Chemother Pharmacol. 2023 Mar;91(3):239-246. doi: 10.1007/s00280-023-04510-1. Epub 2023 Mar 8. Cancer Chemother Pharmacol. 2023. PMID: 36884068 Free PMC article.
399 results